PRMT1 and cardiac hypertrophy: By treating NRCMs with the PRMT1 enzymatic inhibitor CID2818500, PRMT1 siRNA and PRMT1 plasmid, we found that PRMT1 and its enzymatic activity protected against cardiac hypertrophy and cardiac fibrosis in vitro (Fig. 5), this result was consistent with the phenotypes previously reported in PRMT1-knockout mice [21].